• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对一系列强效和选择性线性速激肽 NK(2)受体拮抗剂的 C 端和 N 端部分进行调制。

Modulation on C- and N-terminal moieties of a series of potent and selective linear tachykinin NK(2) receptor antagonists.

机构信息

Chemistry Department, Menarini Ricerche S.p.A. Via Sette Santi 3, 50131 Florence, Italy.

出版信息

ChemMedChem. 2010 Jan;5(1):65-78. doi: 10.1002/cmdc.200900389.

DOI:10.1002/cmdc.200900389
PMID:19957262
Abstract

Herein we describe the synthesis of a series of new potent tachykinin NK(2) receptor antagonists by the modulation of the C- and N-terminal moieties of ibodutant (MEN 15596, 1). The N-terminal benzo[b]thiophene ring was replaced by different substituted naphthalenes and benzofurans, while further modifications were evaluated at the C-terminal tetrahydropyran moiety. Most compounds demonstrated a high affinity for the human NK(2) receptor and high in vitro antagonist potency, indicating that a wide range of substituents at both termini can be incorporated in the molecule without detrimental effects on the interactions with the NK(2) receptor. Selected compounds were tested in vivo confirming their activity as NK(2) antagonists. In particular, after both iv and id administration to guinea pig, compound 61 b was able to antagonize NK(2)-induced colonic contractions with a potency and duration-of-action fully comparable to the reference compound 1 (MEN 15596, ibodutant).

摘要

在此,我们描述了一系列新的强效速激肽 NK(2)受体拮抗剂的合成,方法是调节伊博特坦(MEN 15596,1)的 C 端和 N 端部分。用不同取代的萘和苯并呋喃取代 N 端苯并[b]噻吩环,同时在 C 端四氢吡喃部分进行进一步修饰。大多数化合物对人 NK(2)受体表现出高亲和力和高体外拮抗活性,表明在分子的两端可以引入广泛的取代基,而不会对与 NK(2)受体的相互作用产生不利影响。选择的化合物在体内进行了测试,证实了它们作为 NK(2)拮抗剂的活性。特别是,化合物 61b 在豚鼠体内 iv 和 id 给药后,能够拮抗 NK(2)诱导的结肠收缩,其效力和作用持续时间与参比化合物 1(MEN 15596,伊博特坦)完全相当。

相似文献

1
Modulation on C- and N-terminal moieties of a series of potent and selective linear tachykinin NK(2) receptor antagonists.对一系列强效和选择性线性速激肽 NK(2)受体拮抗剂的 C 端和 N 端部分进行调制。
ChemMedChem. 2010 Jan;5(1):65-78. doi: 10.1002/cmdc.200900389.
2
MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.MEN15596,一种新型非肽类速激肽NK2受体拮抗剂。
Eur J Pharmacol. 2006 Nov 7;549(1-3):140-8. doi: 10.1016/j.ejphar.2006.08.021. Epub 2006 Aug 26.
3
Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists.新型强效选择性线性速激肽NK2受体拮抗剂的发现
J Med Chem. 2007 Oct 4;50(20):4793-807. doi: 10.1021/jm070289w. Epub 2007 Sep 12.
4
alpha,alpha-Cyclopentaneglycine dipeptides capped with biaryls as tachykinin NK(2) receptor antagonists.以联芳基为封端基团的α,α-环戊烷甘氨酸二肽作为速激肽NK(2)受体拮抗剂。
ChemMedChem. 2008 Jul;3(7):1048-60. doi: 10.1002/cmdc.200800018.
5
MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.MEN 11420(奈帕他定),一种新型糖基化双环肽速激肽NK2受体拮抗剂。
Br J Pharmacol. 1998 Jan;123(1):81-91. doi: 10.1038/sj.bjp.0701587.
6
Insertion of an aspartic acid moiety into cyclic pseudopeptides: synthesis and biological characterization of potent antagonists for the human Tachykinin NK-2 receptor.将天冬氨酸部分插入环拟肽:人速激肽NK-2受体强效拮抗剂的合成与生物学特性研究
J Med Chem. 2004 Dec 30;47(27):6935-47. doi: 10.1021/jm040832y.
7
Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.MEN 11467的药理学:一种新型强效、选择性且口服有效的拟肽速激肽NK(1)受体拮抗剂。
Neuropeptides. 2001 Jun-Aug;35(3-4):137-47. doi: 10.1054/npep.2001.0855.
8
Antagonist profile of ibodutant at the tachykinin NK(2) receptor in guinea pig isolated bronchi.伊布地坦在豚鼠离体支气管上对速激肽 NK(2)受体的拮抗作用特征。
Eur J Pharmacol. 2013 Nov 15;720(1-3):180-5.
9
Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor.6-甲基苯并[b]噻吩-2-羧酸(1-[(S)-1-苄基-4-[4-(四氢吡喃-4-基甲基)哌嗪-1-基]丁基氨基甲酰基]环戊基)酰胺的结构-活性关系,一种新型的神经激肽-2 受体拮抗剂。
J Med Chem. 2010 May 27;53(10):4148-65. doi: 10.1021/jm100176s.
10
Modification of the potent peptide FK888 with unusual aminoacids: effects on activity on neurokinin receptors.用非天然氨基酸修饰强效肽FK888:对神经激肽受体活性的影响。
Farmaco. 1996 Mar;51(3):197-201.

引用本文的文献

1
Synthesis, Biological Evaluation, and Binding Mode of a New Class of Oncogenic K-Ras4b Inhibitors.新型致癌性 K-Ras4b 抑制剂的合成、生物学评价及结合模式。
ChemMedChem. 2022 Nov 18;17(22):e202200392. doi: 10.1002/cmdc.202200392. Epub 2022 Sep 23.
2
Synthesis and Biological Evaluation of Benzo[]thiophene Acylhydrazones as Antimicrobial Agents against Multidrug-Resistant .苯并噻吩甲酰腙类化合物的合成及抗多重耐药菌活性评价
Biomolecules. 2022 Jan 14;12(1):131. doi: 10.3390/biom12010131.
3
Methanolysis of the Cyclic Acetal Function of NanoKid Catalyzed by NanoGoblin, the Pyridinium Salt of Tetracyanocyclopentadienide.
由四氰基环戊二烯吡啶盐纳米哥布林催化的纳米小子环状缩醛官能团的甲醇解反应
ACS Omega. 2017 Nov 30;2(11):8543-8549. doi: 10.1021/acsomega.7b01748.